Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Points - Tango Therapeutics, Inc. announced the grant of stock options and restricted stock units (RSUs) to a new employee as part of its 2023 Inducement Plan [1][2] - The stock options granted total 367,500 shares with an exercise price of $11.94 per share, equal to the closing price on the grant date [3] - The RSUs granted total 60,000 shares, with a vesting schedule over three years [3] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [4] - The company utilizes the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related pathways [4]